Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case reportReportar como inadecuado




Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Research Notes

, 7:688

Pharmacology and Toxicology

Abstract

BackgroundGenetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches.

Case presentationWe report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxicity myalgia and moderate creatine kinase elevation.

ConclusionsThe obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9*3 variant in combination with multidrug resistance-associated protein MRP2 -24C > T functions as risk factor predisposing to experience drug-drug interaction combing those drugs.

KeywordsFluvastatin OATP1B1 CYP2C9 Cytochrome P450 Telmisartan Genetic polymorphisms Drug transporter Drug-drug interaction AbbreviationsAT1Angiotensin II receptor type 1

BCRPBreast cancer resistance protein

CKCreatine kinase

CYPCytochrome P450

DNADeoxyribonucleic acid

HMG-CoA3-hydroxy-3-methylglutaryl-coenzyme A

INRInternational normalized ratio

MRPMulti-resistance protein

OATPOrganic anion-transporting polypeptide

PCRPolymerase chain reaction

SNPSingle-nucleotide polymorphism.

Electronic supplementary materialThe online version of this article doi:10.1186-1756-0500-7-688 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Henriette E Meyer zu Schwabedissen - Werner Siegmund - Heyo K Kroemer - Jens D Rollnik

Fuente: https://link.springer.com/







Documentos relacionados